{
    "clinical_study": {
        "@rank": "45277", 
        "arm_group": {
            "arm_group_label": "Neratinib", 
            "arm_group_type": "Experimental", 
            "description": "240mg neratinib"
        }, 
        "brief_summary": {
            "textblock": "This is an open-label, multicenter, multinational, Phase 2 study exploring the efficacy and\n      safety of neratinib therapy in patients with solid tumors with activating HER2, HER3 or EGFR\n      mutations or with EGFR gene amplification."
        }, 
        "brief_title": "An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, multicenter, multinational, Phase 2 study exploring the efficacy and\n      safety of neratinib therapy in patients with solid tumors with activating HER2, HER3 or EGFR\n      mutations or with EGFR gene amplification. The trial will consist of a screening period, a\n      treatment period, and an end-of-treatment visit occurring when neratinib is discontinued for\n      any reason, a safety-follow-up visit occurring 28 to 42 days after the last dose of\n      neratinib and a survival follow-up period lasting for a maximum of 12 months for each\n      patient after their last dose of neratinib or until initiation of additional anti-cancer\n      therapy.\n\n      Treatment will consist of neratinib 240 mg by mouth with food once daily."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed cancers for which no curative therapy exists.\n\n          -  Documented HER2 mutation.\n\n        Exclusion Criteria:\n\n          -  Prior treatment with any pan-HER TKI (eg, lapatinib, afatinib, dacomitinib,\n             neratinib).\n\n          -  Patients who are receiving any other anticancer agents.\n\n          -  Symptomatic or unstable brain metastases.\n\n          -  Women who are pregnant or breast-feeding.\n\n        Note: There are additional inclusion and exclusion criteria. The study center will\n        determine if you meet all of the criteria."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01953926", 
            "org_study_id": "PUMA-NER-5201", 
            "secondary_id": "2013-002872-42"
        }, 
        "intervention": {
            "arm_group_label": "Neratinib", 
            "description": "240 mg orally, once daily with food, continuously in 28 day cycles", 
            "intervention_name": "Neratinib", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Bladder/urinary tract cancer, Colorectal cancer, CRC, Endometrial cancer, Ovarian cancer,", 
            "Gastric cancer, Esophageal cancer, Solid tumors"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Deaconess Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "MD Anderson Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28040"
                    }, 
                    "name": "Hospital Universitario Fundacion Jimenez Diaz"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28050"
                    }, 
                    "name": "Hospital Universitario Madrid Sanchinarro (START Madrid)"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Spain"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Multicenter, Multinational, Phase 2 Study Exploring the Efficacy and Safety of Neratinib Therapy in Patients With Solid Tumors With Activating HER2, HER3 or EGFR Mutations or With EGFR Gene Amplification.", 
        "overall_contact": {
            "email": "ClinicalTrials@pumabiotechnology.com", 
            "last_name": "Puma Biotechnology, Clinical Operations", 
            "phone": "(424) 248-6500"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of this study is to determine the objective response rate at 8 weeks (ORR8) following treatment with neratinib in patients with HER2 (ERBB2), HER3 (ERBB3) or EGFR mutation-positive solid tumors or with EGFR gene amplification.", 
            "measure": "Objective Response Rate at 8 weeks (ORR8)", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01953926"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Secondary Outcome Measure Description is to determine the best confirmed overall response rate (ORR) with neratinib in patients with HER2, HER3 or EGFR mutation-positive solid tumors or with EGFR gene amplification.", 
                "measure": "Overall Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Estimated 6 months"
            }, 
            {
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Estimated 18 months"
            }, 
            {
                "description": "Clinical benefit rate (CBR) is defined as the percentage of patients with complete response (CR) + partial response (PR) + stable disease (SD) \u226516 weeks from the date of enrollment", 
                "measure": "Clinical Benefit Rate (CBR)", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "description": "Duration of response (DOR) is defined as the time from which measurement criteria are met for CR or PR (whichever status is recorded first) until the first date of documented disease progression.", 
                "measure": "Duration of Response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "Estimated 1 year"
            }, 
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Estimated 2 years"
            }, 
            {
                "measure": "Safety (Adverse Events [AEs] and Serious Adverse Events [SAEs])", 
                "safety_issue": "Yes", 
                "time_frame": "From consent through 28 days following treatment completion (estimated 6 months)"
            }
        ], 
        "source": "Puma Biotechnology, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Puma Biotechnology, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}